MobileODT and Partners to Launch First Wide-Scale Deployment of AI screening for Cervical Cancer
MobileODT, developer of the Enhanced Visual Assessment (EVA) System, will partner with Genworks and Apollo Hospitals to deliver its FDA-cleared…
Exscientia Initiates Sixth AI Drug Discovery Partnership
Exscientia to receive up to CHF 67 million in upfront payments, research support, and milestone payments in discovery collaboration with…
Marler Clark: Managing Partner Bill Marler travels to South Africa to address Food Focus Listeria Conference
The Food Focus Conference comes during the largest Listeria outbreak in history which is centered in South Africa. To date,…
Tabuk Pharmaceuticals Signs a Commercial Agreement with Renapharma AB
Tabuk Pharmaceuticals Manufacturing Company (‘Tabuk’), one of the leading pharmaceutical companies in the Middle East and North Africa region, has entered…
Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology
– In subgroup analyses, an overall response rate of 45.5 percent with DS-3201 was observed in patients with B-cell lymphomas…